It is important to note that while HDAC inhibition enhanced the remarkable anti-cancer effects of IL-13-PE in pancreatic cancer models in vivo by upregulating IL-13Rα2 in the tumors, no significant upregulation of IL-13Rα2 expression was observed in any vital organs. This evidence concerns the gene IL13RA2 and familial pancreatic carcinoma.